Dabrafenib/Trametinib, BRAF or BRAF AND MEK Pre-op With BRAF and MEK Post-op, Phase IIB, Melanoma With Brain Mets,Biomarkers and Metabolites

NCT01978236 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

6

Enrollment

INDUSTRY

Sponsor class

Stopped This study was terminated due to the limited enrollment.

Conditions

Melanoma and Brain Metastases

Interventions

DRUG: Dabrafenib 150 mg
DRUG: Trametinib 2.0 mg

Sponsor

GlaxoSmithKline